The briefing
An editorial discusses the growing burden of chronic and rare diseases in an aging U.S. population and the potential role of therapies such as Hybryte. It also considers how federal policy could influence access and innovation.
Original headline
Chronic Rare Diseases In An Aging America: Why Hybryte And Federal Policy Matter Now